LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.

    Bairey, Osnat / Lebel, Eyal / Buxbaum, Chen / Porges, Tzvika / Taliansky, Alisa / Gurion, Ronit / Goldschmidt, Neta / Shina, Tzahala Tzuk / Zektser, Miri / Hofstetter, Liron / Siegal, Tali

    Hematological oncology

    2023  Band 41, Heft 5, Seite(n) 838–847

    Abstract: Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield ... ...

    Abstract Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield information that might prove useful for the future design of randomized clinical trials. We retrospectively analyzed the data of 222 newly diagnosed PCNSL patients treated in five referral centers in Israel between 2001 and 2020. During this period, combination therapy became the treatment of choice, rituximab has been added to the induction therapy, and consolidation with irradiation was largely laid off and was mostly replaced by high-dose chemotherapy with or without autologous stem cell transplantation (HDC-ASCT). Patients older than 60 comprised 67.5% of the study population. First-line treatment included high-dose methotrexate (HD-MTX) in 94% of patients with a median MTX dose of 3.5 g/m
    Mesh-Begriff(e) Humans ; Retrospective Studies ; Rituximab/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prospective Studies ; Rare Diseases/drug therapy ; Rare Diseases/etiology ; Central Nervous System Neoplasms/drug therapy ; Transplantation, Autologous ; Methotrexate ; Lymphoma/pathology ; Central Nervous System/pathology
    Chemische Substanzen Rituximab (4F4X42SYQ6) ; Methotrexate (YL5FZ2Y5U1)
    Sprache Englisch
    Erscheinungsdatum 2023-07-05
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3198
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1816: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.

    Bairey, Osnat / Taliansky, Alisa / Glik, Amir / Amiel, Alexandra / Yust-Katz, Shlomit / Gurion, Ronit / Zektser, Miri / Porges, Tzvika / Sarid, Nadav / Horowitz, Netanel A / Shina, Tzahala Tzuk / Lebel, Eyal / Cohen, Amos / Geiger, Karyn Revital / Raanani, Pia / Wolach, Ofir / Siegal, Tali

    Cancer

    2023  Band 129, Heft 24, Seite(n) 3905–3914

    Abstract: Background: Elderly patients account for nearly 70% of all primary central nervous system lymphoma (PCNSL) cases. They cannot tolerate aggressive treatment and have poor prognosis with a median overall survival (OS) of less than 2 years and progression- ... ...

    Abstract Background: Elderly patients account for nearly 70% of all primary central nervous system lymphoma (PCNSL) cases. They cannot tolerate aggressive treatment and have poor prognosis with a median overall survival (OS) of less than 2 years and progression-free survival (PFS) of 6-16 months. Ibrutinib penetrates the blood-brain barrier and has shown activity in PCNSL.
    Methods: This prospective study investigated whether ibrutinib maintenance is feasible, and whether it can benefit elderly PCNSL patients in terms of expected 2-year PFS. It is an open label, phase 2 study in newly diagnosed PCNSL patients 60-85 years old who responded to first-line high-dose methotrexate (HDMTX)-based treatment with partial or complete response. Ibrutinib maintenance (560 mg/d) was continued until disease progression or intolerable toxicity.
    Results: Twenty patients were enrolled, with a median age of 72 years (range, 61-80). Median time on ibrutinib maintenance was 12.5 (range, 2-46) months. Twelve patients stopped treatment: five due to central nervous system relapse and seven due to adverse events that were mainly grade 2. Five patients died (25%) all due to relapse. The 1- and 2-year PFS are 90% and 72.6%, respectively, and the 2-year OS is 89%.
    Conclusions: The study reached its primary end points and also showed that ibrutinib maintenance is tolerated reasonably well by the elderly. Therefore, this study supports the concept that ibrutinib maintenance should be further evaluated as an optional consolidation measure in the elderly.
    Mesh-Begriff(e) Humans ; Aged ; Middle Aged ; Aged, 80 and over ; Methotrexate ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/pathology ; Lymphoma/therapy ; Recurrence ; Central Nervous System/pathology ; Central Nervous System Neoplasms/therapy ; Retrospective Studies
    Chemische Substanzen Methotrexate (YL5FZ2Y5U1) ; ibrutinib (1X70OSD4VX)
    Sprache Englisch
    Erscheinungsdatum 2023-08-12
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34985
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.146: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang